Anti-Tumor Necrosis Factor α–Related Psoriatic Lesions in Children with Inflammatory Bowel Disease: Case Report and Systematic Literature Review
Ricardo Romiti M.D., Ph.D.
Department of Dermatology, School of Medical Sciences, Universidade de São Paulo, São Paulo, Brazil
Search for more papers by this authorKarin Milleni Araujo M.D.
Department of Dermatology, School of Medical Sciences, Universidade de São Paulo, São Paulo, Brazil
Search for more papers by this authorFlavio Steinwurz M.D., M.Sc.
Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil
Search for more papers by this authorCorresponding Author
Rafael Denadai M.D.
Department of Dermatology, School of Medical Sciences, Universidade de São Paulo, São Paulo, Brazil
SOBRAPAR Hospital, Campinas, Brazil
Address correspondence to Rafael Denadai, M.D., SOBRAPAR Hospital, Av. Adolpho Lutz, 100, Caixa Postal: 6028, Campinas, São Paulo CEP: 13084-880, Brazil, or e-mail: [email protected]Search for more papers by this authorRicardo Romiti M.D., Ph.D.
Department of Dermatology, School of Medical Sciences, Universidade de São Paulo, São Paulo, Brazil
Search for more papers by this authorKarin Milleni Araujo M.D.
Department of Dermatology, School of Medical Sciences, Universidade de São Paulo, São Paulo, Brazil
Search for more papers by this authorFlavio Steinwurz M.D., M.Sc.
Unit of Inflammatory Bowel Disease, Hospital Israelita Albert Einstein, São Paulo, Brazil
Search for more papers by this authorCorresponding Author
Rafael Denadai M.D.
Department of Dermatology, School of Medical Sciences, Universidade de São Paulo, São Paulo, Brazil
SOBRAPAR Hospital, Campinas, Brazil
Address correspondence to Rafael Denadai, M.D., SOBRAPAR Hospital, Av. Adolpho Lutz, 100, Caixa Postal: 6028, Campinas, São Paulo CEP: 13084-880, Brazil, or e-mail: [email protected]Search for more papers by this authorAbstract
We report a child with Crohn's disease and infliximab-induced guttate psoriasis. We also performed a systematic literature review on this intriguing paradoxical phenomenon in children with inflammatory bowel disease.
References
- 1Steinwurz F, Denadai R, Saad-Hossne R et al. Infliximab-induced psoriasis during therapy for Crohn's disease. J Crohns Colitis 2012; 6: 610–616.
- 2Denadai R, Teixeira FV, Steinwurz F et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 2013; 7: 517–524.
- 3Mälkönen T, Wikström A, Heiskanen K et al. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis 2014; 20: 1309–1315.
- 4George LA, Gadani A, Cross RK et al. Psoriasiform skin lesions are caused by anti-TNF agents used for the treatment of inflammatory bowel disease. Dig Dis Sci 2015; 60: 3424–3430.
- 5Costa-Romero M, Coto-Segura P, Suarez-Saavedra S et al. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm Bowel Dis 2008; 14: 1462–1463.
- 6Avila Alvarez A, García-Alonso L, Solar Boga A et al. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease. An Pediatr (Barc) 2008; 70: 278–281.
- 7Pourciau C, Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol 2010; 27: 539–540.
- 8Conklin LS, Cohen B, Wilson L et al. Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. Nat Rev Gastroenterol Hepatol 2010; 7: 174–177.
- 9Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 52: 230–232.
- 10Perman MJ, Lovell DJ, Denson LA et al. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol 2012; 29: 454–459.
- 11Sherlock ME, Walters T, Tabbers MM et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr 2013; 56: 512–518.
- 12Broge T, Nguyen N, Sacks A et al. Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy. Inflamm Bowel Dis 2013; 19: E75–E77.
- 13García Morin M, González Ruiz De León E, Tolín Hernani M et al. Infliximab-induced psoriasis in an adolescent with ulcerative colitis. An Pediatr (Barc) 2014; 80: e18–e19.
- 14Ribeiro LB, Rego JC, Estrada BD et al. Alopecia secondary to anti-tumor necrosis factor-alpha therapy. An Bras Dermatol 2015; 90: 232–235.
- 15Mercy K, Kwasny M, Cordoro KM et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol 2013; 30: 424–428.
Citing Literature
